Sep 21, 2023
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
Aug 03, 2023
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
Jul 27, 2023
Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
Jul 19, 2023
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
Jun 21, 2023
Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
Jun 07, 2023
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
May 24, 2023
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
May 12, 2023
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
May 04, 2023
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
Apr 27, 2023
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
Displaying 1 - 10 of 19